1.
Euro Surveill
; 27(33)2022 08.
Artículo
en Inglés
| MEDLINE
| ID: mdl-35983774
RESUMEN
In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR)â¯=â¯0.08; 95% confidence interval (CI): 0.05-0.13) but not with anti-S antibodies (aORâ¯=â¯1.06; 95% CI: 0.47-2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.